A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors

Current treatments for advanced solid tumors tend to be only palliative. Although radiotherapy is administered with a curative intent, radioresistance and dose-limiting toxicities pose limitations to treatment. Abexinostat, an oral pan-histone deacetylase inhibitor, demonstrated enhanced sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Deutsch, Eric, Moyal, Elizabeth Cohen-Jonathan, Gregorc, Vanesa, Zucali, Paolo Andrea, Menard, Jean, Soria, Jean-Charles, Kloos, Ioana, Hsu, Jeff, Luan, Ying, Liu, Emily, Vezan, Remus, Graef, Thorsten, Rivera, Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593555/
https://www.ncbi.nlm.nih.gov/pubmed/28915584
http://dx.doi.org/10.18632/oncotarget.14147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593555/
https://www.ncbi.nlm.nih.gov/pubmed/28915584
http://dx.doi.org/10.18632/oncotarget.14147

Ejemplares similares